Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Vir and Alnylam Expand their 2017 License Agreement to Target COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post